Asset Details
Do you wish to reserve the book?
Fondaparinux Compared with Enoxaparin for the Prevention of Venous Thromboembolism after Elective Major Knee Surgery
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Fondaparinux Compared with Enoxaparin for the Prevention of Venous Thromboembolism after Elective Major Knee Surgery
Do you wish to request the book?
Fondaparinux Compared with Enoxaparin for the Prevention of Venous Thromboembolism after Elective Major Knee Surgery
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Fondaparinux Compared with Enoxaparin for the Prevention of Venous Thromboembolism after Elective Major Knee Surgery
2001
Overview
Major knee surgery poses a considerable risk of postoperative venous thromboembolism. In this study, fondaparinux, a new antithrombotic pentasaccharide, was found to surpass the ability of enoxaparin, a low-molecular-weight heparin, to prevent venous thromboembolism after knee surgery.
Fondaparinux, a new antithrombotic pentasaccharide, was found to surpass the ability of enoxaparin to prevent venous thromboembolism after knee surgery.
Venous thromboembolism is a frequent, life-threatening postoperative complication of total-knee-replacement surgery.
1
,
2
Without thromboprophylaxis, the prevalence rate is 40 to 84 percent for venographically verified postoperative deep-vein thrombosis and 2 to 7 percent for pulmonary embolism.
1
Thromboprophylaxis that is effective in hip-replacement surgery, such as low-dose heparin, low-molecular-weight heparin, or warfarin, is less successful in knee-replacement surgery and reduces the prevalence of deep-vein thrombosis only to 31 to 47 percent.
1
For this reason, more effective antithrombotic prophylaxis is needed in knee-replacement surgery.
Fondaparinux is one of a new class of antithrombotic agents, the selective inhibitors of activated factor X (factor . . .
Publisher
Massachusetts Medical Society
Subject
/ Biological and medical sciences
/ Blood. Blood coagulation. Reticuloendothelial system
/ Drug Administration Schedule
/ Elective Surgical Procedures
/ Enoxaparin - adverse effects
/ Enoxaparin - therapeutic use
/ Female
/ Fibrinolytic Agents - adverse effects
/ Fibrinolytic Agents - therapeutic use
/ Hemorrhage - chemically induced
/ Humans
/ Male
/ Pharmacology. Drug treatments
/ Polysaccharides - adverse effects
/ Polysaccharides - therapeutic use
/ Postoperative Complications - prevention & control
/ Pulmonary Embolism - prevention & control
/ Surgery
/ Thromboembolism - epidemiology
